Exhibit
32.1
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED
PURSUANT TO
SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly
Report on Form 10-Q of Monopar Therapeutics Inc. (the Company) for
the three months ended March 31, 2021, as filed with the Securities
and Exchange Commission on the date hereof (the Report), we,
Chandler D. Robinson, and Kim R. Tsuchimoto, hereby certify,
pursuant to 18 U.S.C. §1350, as adopted pursuant to §906
of the Sarbanes-Oxley Act of 2002, that:
(1) the Report fully
complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and
(2) the information
contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the
Company.
/s/ Chandler D.
Robinson
Chandler D. Robinson
Chief Executive Officer
May 13, 2021
/s/ Kim R.
Tsuchimoto
Kim R. Tsuchimoto
Chief Financial Officer
May 13, 2021
This
certification accompanies the Form 10-Q to which it relates, is not
deemed filed with the Securities and Exchange Commission and is not
to be incorporated by reference into any filing of Monopar
Therapeutics Inc. under the Securities Act of 1933, as amended, or
the Securities Exchange Act of 1934, as amended (whether made
before or after the date of the Form 10-Q), irrespective of any
general incorporation language contained in such
filing.